Free Trial
→ The only 5 stocks that matter (From TradeSmith) (Ad)tc pixel Free CLBX Stock Alerts

Cellbxhealth (CLBX) Competitors

GBX 0.84 +0.07 (+8.39%)
As of 10/2/2026 11:36 AM Eastern
Compare

CLBX vs. HEMO, C4XD, DDDD, COIL, and OKYO

Should you buy Cellbxhealth stock or one of its competitors? Cellbxhealth's main competitors and comparable companies include Hemogenyx Pharmaceuticals (HEMO), C4X Discovery (C4XD), 4D pharma (DDDD), Roquefort Therapeutics (COIL), and OKYO Pharma (OKYO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cellbxhealth compare to Hemogenyx Pharmaceuticals?

Cellbxhealth (LON:CLBX) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Cellbxhealth's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
Hemogenyx Pharmaceuticals N/A -409.57%-37.79%

0.4% of Cellbxhealth shares are held by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 1.2% of Cellbxhealth shares are held by insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cellbxhealth has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£1.15M8.29N/A-£3.49N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

In the previous week, Hemogenyx Pharmaceuticals had 6 more articles in the media than Cellbxhealth. MarketBeat recorded 6 mentions for Hemogenyx Pharmaceuticals and 0 mentions for Cellbxhealth. Hemogenyx Pharmaceuticals' average media sentiment score of 0.37 beat Cellbxhealth's score of 0.00 indicating that Hemogenyx Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Cellbxhealth Neutral
Hemogenyx Pharmaceuticals Neutral

Summary

Cellbxhealth beats Hemogenyx Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Cellbxhealth compare to C4X Discovery?

C4X Discovery (LON:C4XD) and Cellbxhealth (LON:CLBX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

C4X Discovery has a net margin of 42.81% compared to Cellbxhealth's net margin of 0.00%. C4X Discovery's return on equity of 55.38% beat Cellbxhealth's return on equity.

Company Net Margins Return on Equity Return on Assets
C4X Discovery42.81% 55.38% 28.04%
Cellbxhealth N/A N/A N/A

52.1% of C4X Discovery shares are held by institutional investors. Comparatively, 0.4% of Cellbxhealth shares are held by institutional investors. 27.1% of C4X Discovery shares are held by company insiders. Comparatively, 1.2% of Cellbxhealth shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, C4X Discovery's average media sentiment score of 0.00 equaled Cellbxhealth'saverage media sentiment score.

Company Overall Sentiment
C4X Discovery Neutral
Cellbxhealth Neutral

C4X Discovery has higher revenue and earnings than Cellbxhealth. Cellbxhealth is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
C4X Discovery£24.68M0.00£10.57M£0.04N/A
Cellbxhealth£1.15M8.29N/A-£3.49N/A

Summary

C4X Discovery beats Cellbxhealth on 8 of the 8 factors compared between the two stocks.

How does Cellbxhealth compare to 4D pharma?

4D pharma (LON:DDDD) and Cellbxhealth (LON:CLBX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

Cellbxhealth has higher revenue and earnings than 4D pharma. Cellbxhealth is trading at a lower price-to-earnings ratio than 4D pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4D pharma£718K0.00-£31.94M-£15.40N/A
Cellbxhealth£1.15M8.29N/A-£3.49N/A

Cellbxhealth's return on equity of 0.00% beat 4D pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
4D pharmaN/A -89.48% -42.64%
Cellbxhealth N/A N/A N/A

26.8% of 4D pharma shares are owned by institutional investors. Comparatively, 0.4% of Cellbxhealth shares are owned by institutional investors. 12.2% of 4D pharma shares are owned by insiders. Comparatively, 1.2% of Cellbxhealth shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, 4D pharma had 1 more articles in the media than Cellbxhealth. MarketBeat recorded 1 mentions for 4D pharma and 0 mentions for Cellbxhealth. 4D pharma's average media sentiment score of 0.00 equaled Cellbxhealth'saverage media sentiment score.

Company Overall Sentiment
4D pharma Neutral
Cellbxhealth Neutral

Summary

Cellbxhealth beats 4D pharma on 5 of the 8 factors compared between the two stocks.

How does Cellbxhealth compare to Roquefort Therapeutics?

Cellbxhealth (LON:CLBX) and Roquefort Therapeutics (LON:COIL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Cellbxhealth has higher revenue and earnings than Roquefort Therapeutics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£1.15M8.29N/A-£3.49N/A
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A

Cellbxhealth has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Cellbxhealth's return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
Roquefort Therapeutics -57,057.07%-18.71%-15.86%

0.4% of Cellbxhealth shares are owned by institutional investors. Comparatively, 1.8% of Roquefort Therapeutics shares are owned by institutional investors. 1.2% of Cellbxhealth shares are owned by insiders. Comparatively, 36.1% of Roquefort Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Roquefort Therapeutics had 5 more articles in the media than Cellbxhealth. MarketBeat recorded 5 mentions for Roquefort Therapeutics and 0 mentions for Cellbxhealth. Roquefort Therapeutics' average media sentiment score of 0.61 beat Cellbxhealth's score of 0.00 indicating that Roquefort Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Cellbxhealth Neutral
Roquefort Therapeutics Positive

Summary

Cellbxhealth beats Roquefort Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Cellbxhealth compare to OKYO Pharma?

Cellbxhealth (LON:CLBX) and OKYO Pharma (LON:OKYO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

Cellbxhealth's return on equity of 0.00% beat OKYO Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
OKYO Pharma N/A -397.13%-154.72%

Cellbxhealth has higher revenue and earnings than OKYO Pharma. Cellbxhealth is trading at a lower price-to-earnings ratio than OKYO Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£1.15M8.29N/A-£3.49N/A
OKYO PharmaN/AN/A-£6.70M-£0.01N/A

0.4% of Cellbxhealth shares are owned by institutional investors. 1.2% of Cellbxhealth shares are owned by company insiders. Comparatively, 31.9% of OKYO Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, OKYO Pharma had 1 more articles in the media than Cellbxhealth. MarketBeat recorded 1 mentions for OKYO Pharma and 0 mentions for Cellbxhealth. Cellbxhealth's average media sentiment score of 0.00 beat OKYO Pharma's score of -1.19 indicating that Cellbxhealth is being referred to more favorably in the media.

Company Overall Sentiment
Cellbxhealth Neutral
OKYO Pharma Negative

Summary

Cellbxhealth beats OKYO Pharma on 6 of the 9 factors compared between the two stocks.

Get Cellbxhealth News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLBX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLBX vs. The Competition

Export
MetricCellbxhealthBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£9.38M£3.85B£7.16B£2.46B
Dividend YieldN/A3.65%2.53%6.25%
P/E Ratio-0.2413.00274.69366.33
Price / Sales8.291,292.30610.1389,426.82
Price / CashN/A39.0427.2227.89
Price / BookN/A16.5810.976.83
Net IncomeN/A-£23.20M£3.50B£5.89B
7 Day Performance0.84%-2.97%-2.00%-0.72%
1 Month Performance-25.33%-10.82%-6.19%-1.01%
1 Year PerformanceN/A19.00%8.03%22.82%

Cellbxhealth Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLBX
Cellbxhealth
N/AGBX 0.84
+8.4%		N/AN/A£9.38M£1.15MN/A114
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 478.50
+3.1%		N/A-39.8%£32.54MN/AN/A14
C4XD
C4X Discovery
N/AN/AN/AN/A£30.27M£24.68M300.0049
DDDD
4D pharma
N/AN/AN/AN/A£30.05M£718KN/A106
COIL
Roquefort Therapeutics
N/AGBX 6.93
-2.6%		N/A-63.7%£29.59MN/AN/A9

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CLBX) was last updated on 10/4/2026 by MarketBeat.com Staff.
From Our Partners
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...
American Hartford Gold | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
How Elon’s Empire Ends (and how to profit)
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...
Chaikin Analytics | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
WATCH THIS BEFORE DECEMBER 8th!!
James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...
Paradigm Press | Sponsoredtc pixel
A new kind of civil war is coming after election day?
Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...
Stansberry Research | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel